DOCTR Resource Center Planning

DOCTR资源中心规划

• 批准号: 9001772
• 负责人: BENJAMIN M WU
• 金额: $ 19.25万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-10 至 2017-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9001772
• 关键词: Amaze; Animal Model; Biological Assay; Cessation of life; Deglutition; Dental; Drug Delivery Systems; FDA approved; Goals; Grant; Growth Factor; Institution; Lead; Mastication; Mission; Occupational activity of managing finances; Odontogenesis; Oral; Patients; Phase; Preparation; Quality of life; Research Personnel; Resources; Safety; Schedule; Science; Series; Smiling; Speech; Staging; Stem cells; Structure; Technology; Tissue Engineering; Tissues; Translations; Validation; Work; cell growth; cost effective; craniofacial; daily functioning; meetings; new technology; organizational structure; product development; psychologic; public health relevance; regenerative; scaffold; social; symposium; tissue regeneration

 DESCRIPTION (provided by applicant): Many basic discoveries made by researchers at UCLA, Stanford, and across the nation have led to novel technologies in stem cells, growth factors, drug delivery carriers, and bioactive scaffolding materials. Despite this tremendous progress, very few discoveries manage to advance to FDA approved tissue engineering products. Furthermore, few bioassays and animal models are available for reliable validation of safety and efficacy for the tissue regeneration products. This discrepancy is due to the infamous "Valley of Death" that separates amazing science from patient benefits. The interdisciplinary UCLA-Stanford Dental Oral Craniofacial Tissue Regeneration Center (UCLA-Stanford DOCTRC) is a public-private consortium with the primary mission of providing scientific, technical, regulatory, financial, and management resources to promote cost-effective transition and timely development of dental oral craniofacial tissue regeneration products. During this Stage 1 planning phase, 4 quarterly conferences and und 9 monthly working meetings will be held to 1) develop organizational structure, leverage existing resources, identify unmet resource needs; and 2) Develop Interdisciplinary Translational Project teams to build lead and pipeline DOC tissue regeneration products.

 描述（由申请人提供）：加州大学洛杉矶分校，斯坦福大学和全国各地的研究人员的许多基本发现导致了干细胞，生长因子，药物输送载体和生物活性支架材料的新技术。尽管取得了巨大的进步，但很少有发现能够成功地发展为FDA批准的组织工程产品。此外，很少有生物测定和动物模型可用于可靠验证组织再生产品的安全性和有效性。这种差异是由于臭名昭著的“死亡之谷”将惊人的科学与患者的利益分开。跨学科的UCLA-Stanford Dental Oral Craniofacial Tissue Regeneration Center（UCLA-Stanford DOCTRC）是一个公私合营的财团，其主要使命是提供科学、技术、监管、财务和管理资源，以促进牙科口腔颅面组织再生产品的成本效益过渡和及时开发。在第1阶段规划阶段，将举行4次季度会议和9次月度工作会议，以1）开发组织结构，利用现有资源，确定未满足的资源需求; 2）开发跨学科翻译项目团队，以构建领先和管道DOC组织再生产品。